Comparison of labetalol and nifedipine in control of blood pressure in severe pre-eclampsia in Dalhatu Araf Specialist Hospital

Lucky C. Lohnan; James Bitrus; Francis C. Opara; Mary C. Momoh; Oluwaseye F. Oyeniran; Samuelson Chibuzo

doi:10.18203/2320-1770.ijrcog20250842

Authors

Lucky C. Lohnan Department of Obstetrics and Gynaecology, Dalhatu Araf Specialist Hospital, Lafia, Nasarawa, Nigeria
James Bitrus Bingham University Teaching Hospital, Jos, Plateau, Nigeria
Francis C. Opara Department of Obstetrics and Gynaecology, Dalhatu Araf Specialist Hospital, Lafia, Nasarawa, Nigeria
Mary C. Momoh Department of Obstetrics and Gynaecology, Dalhatu Araf Specialist Hospital, Lafia, Nasarawa, Nigeria
Oluwaseye F. Oyeniran Department of Obstetrics and Gynaecology, Dalhatu Araf Specialist Hospital, Lafia, Nasarawa, Nigeria
Samuelson Chibuzo Department of Obstetrics and Gynaecology, Jos University Teaching Hospital, Jos, Plateau, Nigeria

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20250842

Keywords:

Labetalol, Nifedipine, Severe pre-eclampsia, Blood pressure, DASH

Abstract

Background: Severe preeclampsia and eclampsia are forms of hypertensive disorders of pregnancy that cause significant morbidity and mortality in the mother and foetus globally. The best drug for prompt lowering of blood pressure is required for a desirable outcome. This study was aimed determining the efficacy of intravenous labetalol compared with oral nifedipine in the immediate control of hypertension in severe pre-eclampsia.

Methods: Seventy-four women who fit the criteria for severe preeclampsia were randomly selected and recruited for the prospective comparative study. They were divided into two equal arms, one, receiving intravenous labetalol in precise, timed doses and the other, oral nifedipine in its own timed doses. The doses and time for effective blood pressure control were recorded in both arms and comparatively analyzed.

Results: The time taken to achieve targeted blood pressure of <150/100 mmHg in the intravenous labetalol group was (38.9±17.2 min) and in the oral nifedipine group was (37.1±17.2 min) with p value=0.302. The mean number of doses required to achieve this was (2.6±1.2 doses) and (2.3±1.0 doses) respectively with p value of 0.370. The mean cost of treatment per doses given for labetalol group was (NGN 3259.5±2294.4) and nifedipine group, was (NGN 3254.1±1440.4) with p value=0.990.

Conclusions: Both drugs were found to be equally efficacious in rapidity of controlling blood pressure in severe preeclampsia and both had similar cost effect per dose of drug.

Metrics

Metrics Loading ...

References

Nombur LI, Agida ET, Isah AY, Ekele BA. A Comparison of Hydralazine and Labetalol in the Management of Severe Preeclampsia. J Women’s Health Care. 2014;3(6):200.

Ekele BA. Use of magnesium sulfate to manage pre-eclampsia and eclampsia in Nigeria: overcoming the odds. Ann Afr Med. 2009;8(2):73-5. DOI: https://doi.org/10.4103/1596-3519.56231

Gifford RW, August PA, Cunningham G, Green LA, Lindheimer MD, Sibai BM, et al. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-22.

Redman CWG, Jefferis M. Revised definition of preelcampsia. Lancet. 1988;1:809-12. DOI: https://doi.org/10.1016/S0140-6736(88)91667-4

Pridjan G, Puschett JB. Preeclampsia. Part 1 clinical and pathophysiologic considerations. Obstet Gynecol Surv. 2002;57:598-618. DOI: https://doi.org/10.1097/00006254-200209000-00023

Onyiruka AN, Okolo AA. Perinatal outcome in patients with pre-eclampsia in Benin-City, Nigeria. Trop J Obstet Gynaecol. 2004;21:148-52. DOI: https://doi.org/10.4314/tjog.v21i2.14490

Rana S, Lemoine E, Granger J, Karumanchi S. Preeclampsia Pathophysiology, Challenges, and Perspectives. Circ Res. 2019;124:1094-12. DOI: https://doi.org/10.1161/CIRCRESAHA.118.313276

Kattah AG, Vesna D. Garovic V. The Management of Hypertension in Pregnancy; Adv Chronic Kidney Dis. 2013;20(3):229-39. DOI: https://doi.org/10.1053/j.ackd.2013.01.014

Al-Jameil N, Aziz Khan F, Fareed Khan M, Tabassum H. A brief overview of preeclampsia. J Clin Med Res. 2014;6(1):1-7. DOI: https://doi.org/10.4021/jocmr1682w

Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-31.

Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1-S22. DOI: https://doi.org/10.1067/mob.2000.107928

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955-60. DOI: https://doi.org/10.1136/bmj.327.7421.955

Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, et al. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006;128:157-62. DOI: https://doi.org/10.1016/j.ejogrb.2006.02.015

Royal College of Obstetricians and Gynaecologists. Guideline 10A. Management of severe preeclampsia and eclampsia. 2006. Available at: https://www.rcog. org.uk/guidance/browse-all-guidance/green-top-guidelines/severe-pre-eclampsiaeclampsia-manage ment-green-top-guideline-no-10a/. Accessed on 28 January 2025.

Cunningham FG. Hypertensive disorders in pregnancy. In Williams Obstetrics. 22nd edition. McGraw-Hill, New York. 2005.

Kooffreh ME, Ekott M, Ekpoudom DO. The prevalence of pre‑eclampsia among pregnant women in the University of Calabar Teaching Hospital, Calabar. Saudi J Health Sci. 2014;3:133‑6. DOI: https://doi.org/10.4103/2278-0521.142317

Arulkumaran N, Lightstone L. Severe pre-eclampsia and hypertensive crises. Best Pract Res Clin Obstet Gynaecol. 2013;27(6):877-84. DOI: https://doi.org/10.1016/j.bpobgyn.2013.07.003

Gavit Y, Sharma D, Dixit PV. A comparative study of oral nifedipine and intravenous labetalol in control of acute hypertension in severe pre-eclampsia and eclampsia. Int J Reprod Contracept Obstet Gynecol. 2018;7:719-24. DOI: https://doi.org/10.18203/2320-1770.ijrcog20180201

Hangarga US, Rita D, Harshitha K. Comparative study of labetalol and nifedipine in management of hypertensive disorders in pregnancy. Int J Reprod Contracept Obstet Gynecol. 2017;6:194-7. DOI: https://doi.org/10.18203/2320-1770.ijrcog20164656

Swapan D, Swagata B, Prakash D, Biswajit M. Comparative Study of Intravenous Labetalol and Oral Nifedipine for Control of Blood Pressure in Severe Preeclampsia. J Dent Med Sci. 2015;14:22-7.

Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2012;119:78-85. DOI: https://doi.org/10.1111/j.1471-0528.2011.03151.x

Chawla D. A comparative study of intravenous labetalol versus oral nifedipine in severe hypertension in pregnancy in a tertiary hospital, New Delhi. IOSR J Dent Med Sci. 2018;17(3):56-9.

Vermillion ST, Sardo JA, Newman RB, Chauhan SP. A randomized double-blind trial of Oral nifedipine and intravenous labetalolin hypertensive emergencies of pregnancy. Am J Obstet Gynaecol. 1999;181(4):856-61. DOI: https://doi.org/10.1016/S0002-9378(99)70314-5

Shekhar S, Sharma C, Thakur S, Verma S. Oral Nifedipine or Intravenous Labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol. 2013;122(5):1057-63. DOI: https://doi.org/10.1097/AOG.0b013e3182a9ea68

Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;2013(7):CD001449. DOI: https://doi.org/10.1002/14651858.CD001449.pub3